Clinical trials: Hereditary Pancreatic Cancer
Pancreatic Cancer, Cholangiocarcinoma
Bilioenteric Anastomosis by Magnetic Compressive Technique
The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on bilioenteric anastomosis.
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Bile Duct Injury, Choledochal Cyst
- Trial name
- BAMCT (NCT03774589)
- Testing
- Magnetic Compressive Anastomosis, Manual Anastomosis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase II trial studies ziv-aflibercept in treating and perfusion computed tomography perfusion imaging in predicting response in patients with pancreatic neuroendocrine tumors that have spread to other parts of the body or…
- Trial name
- NCT02101918
- Testing
- Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Carcinoid Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma
- Trial name
- NCT00947167
- Testing
- pertuzumab, erlotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pamela L. Kunz
Familial Pancreatic Cancer
Understanding Genetic Incidental Findings in Your Family (UNIFY Study)
Currently, there is no clear legal or ethical guidance about how researchers and IRBs ought to proceed when the research participant in a biobank is deceased and there is clinically relevant information that could be disclosed to…
- Trial name
- UNIFY (NCT02560896)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas
- Trial name
- NCT05692596
- Testing
- Data collection
- Where
- United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Diseases, Polycystic Ovary
Breast Ultrasonography and Polycystic Ovary Syndrome
The results of the evaluation of breast ultrasonography results of patients with polycystic ovary syndrome diagnosis over 30 years of age will be evaluated.
- Trial name
- NCT04231786
- Testing
- Breast ultrasonography findings
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Fibroadenoma, Breast Fibroadenoma
Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical Excision
The purpose of this study is to evaluate and compare three different management strategies for benign breast fibroadenoma: conservative management with clinical and radiological follow-up (observation), ultrasound-guided…
- Conditions
- Fibroadenoma, Breast Fibroadenoma, Benign Breast Disease
- Trial name
- NCT07890766
- Testing
- Ultrasound-guided percutaneous microwave ablation, Conventional open surgical excision
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy.
- Conditions
- Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
- Trial name
- NCT00892736
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)